Clinical Trial

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Withdrawn Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.
Summary
The main purpose of this study is to investigate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of biomarker-guided novel anticancer agent(s) as monotherapy or combination therapy for the treatment of participants with advanced/recurrent ovarian cancer. Substudy 1 will investigate the safety, tolerability, preliminary efficacy, PK and PD of saruparib monotherapy in participants with BReast CAncer gene (BRCA) mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-10; most recent amendment 2026-03-31.
Status change: Active, Not Recruiting → Withdrawn 2026-02-18
Status change: Recruiting → Active, Not Recruiting 2025-11-19
Status change: Not Yet Recruiting → Recruiting 2025-09-26
Trial Details
NCT Number NCT07060365
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Advanced/Recurrent Ovarian Cancer
Start Date 2025-09-02
Primary Completion 2025-12-19 (estimated)
Study Completion 2025-12-19 (estimated)
Updated on ClinicalTrials.gov 2026-04-03